36 Gordon Square
London WC1H 0PD

T +44 (0) 20 7958 8251
admin@lidc.bloomsbury.ac.uk

Developing world medicines get more money... but is it well directed? Launch of the G-FINDER report 2010

The third annual G-FINDER report launched yesterday reveals both positive and negative trends in global funding of research and development (R&D) of new neglected diseases products in 2009.
Looking at the effects of the global financial crisis, the report discovered that funding increased by $239 million in 2009, mostly coming from public funders (up $259 million) and industry (up $43 million), while philanthropic funding dropped by $63 million. Funding was also better distributed between diseases. However, the worrying trend revealed by the report is that funders are shifting their focus away from the much needed product development towards basic research.
 
Report author Dr Mary Moran, Director of Policy Cures, said:
“Funders need to be careful not to take their eye off the ball. More funding is vital, and encouraging to see, but it’s just as important that the funds are spent wisely and well. Increased public spending on domestic researchers is an understandable strategy in hard economic times, but only if it also achieves the aim of creating new medicines and vaccines for those in the developing world.”
The G-FINDER survey, now in its third year, collects comprehensive data on public and private funding into R&D for neglected diseases like malaria, TB, HIV, pneumonia, sleeping sickness and helminth infections. It covers 31 diseases and 134 product areas, including drugs, vaccines, diagnostics, microbicides and vector control product.
Policy Cures, who has produced the report, is an independent group providing research, information, decision-making tools and strategic analysis for those involved in the creation of new pharmaceuticals for neglected diseases.